Sustanon-250
Sustanon-250: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. Drug interactions
- 12. Analogs
- 13. Terms and conditions of storage
- 14. Terms of dispensing from pharmacies
- 15. Reviews
- 16. Price in pharmacies
Latin name: Sustanon 250
ATX code: G03BA03
Active ingredient: Testosterone (mixture of esters) (Testosterone [mixture of esters])
Manufacturer: ORGANON, NV (Netherlands)
Description and photo update: 2019-07-08
Sustanon-250 is a drug with androgenic action.
Release form and composition
The dosage form of Sustanon-250 is a solution for intramuscular administration: oily, from yellow to almost colorless with a slight yellowish tinge (in glass colorless ampoules of 1 ml, in a cardboard box 1 ampoule).
Active substances (esters of the natural hormone testosterone) in 1 ml of solution:
- testosterone propionate - 30 mg;
- testosterone phenylpropionate - 60 mg;
- testosterone isocapronate - 60 mg;
- testosterone decanoate - 100 mg.
The total testosterone content is 176 mg / 1 ml.
Additional components: nitrogen, benzyl alcohol, peanut oil.
Pharmacological properties
Pharmacodynamics
Testosterone is the main endogenous hormone required for the full growth and development of male genital organs and secondary sexual characteristics. Throughout life in adult men, this compound ensures the functioning of the testes and related structures, the prostate gland and seminal vesicles, and is also responsible for well-being, maintenance of libido and erectile potency.
In the treatment of hypogonadal men with Sustanon-250, there is a clinically significant increase in the concentrations of testosterone, androstenedione, estradiol and dihydrotestosterone in plasma, as well as a decrease in the content of SHBG (globulin that binds sex hormones). Follicle-stimulating hormone and luteinizing hormone levels are restored to normal levels.
Therapy with Sustanon-250 causes a decrease in the symptoms of testosterone deficiency. Muscle mass and bone mineral density also increase, and obese patients experience a decrease in body weight. In the course of treatment, patients' sexual functions, including libido and erectile function, are normalized. When the drug is prescribed, the serum content of triglycerides, low-density lipoproteins and high-density lipoproteins decreases, hemoglobin and hematocrit concentrations increase, but the level of PSA (prostate specific antigen) and liver enzymes remains practically unchanged.
The drug can lead to enlargement of the prostate gland in size, which is not accompanied by functional changes. In hypogonadal patients with diagnosed diabetes mellitus, androgen administration increases insulin sensitivity and / or decreases plasma glucose levels.
In boys who have stunted growth and puberty, testosterone therapy accelerates growth and activates the development of secondary sexual characteristics. Treatment of transgender women with Sustanon-250 promotes virilization.
Pharmacokinetics
The composition of the drug includes a number of progesterone esters with various prolonged action. Once in the bloodstream, they are immediately hydrolyzed to form the natural hormone testosterone.
Taking a single dose of Sustanon-250 causes an increased content of total testosterone in plasma, the maximum concentration of which is approximately 70 nmol / L and is recorded approximately 24–48 hours after administration. In patients, testosterone levels return to the lower normal range after about 21 days.
In vitro tests confirm a high degree of non-specific binding of testosterone to plasma proteins (more than 97%) and SHBG. Testosterone is metabolized naturally to estriol and dihydrotestosterone and excreted via the kidneys as androsterone and etiocholanolone conjugates.
Indications for use
Sustanon-250 is prescribed for testosterone replacement therapy in men with pathological conditions that are associated with congenital / acquired hypogonadism (primary and secondary).
Contraindications
Absolute:
- breast or prostate cancer (diagnosed / suspected);
- age up to 3 years (benzyl alcohol is a part of Sustanon-250);
- pregnancy;
- hypersensitivity to the substances that make up the drug.
Relative (Sustanon-250 is prescribed with caution in the presence of the following diseases / conditions):
- prepubertal period in boys (due to the high likelihood of premature puberty and closure of the pineal glands);
- hepatic / renal failure, chronic heart failure (to avoid the development of edema);
- adenoma of the prostate gland, proceeding with urinary retention;
- diabetes;
- sleep apnea, including the presence of risk factors for its development (chronic lung disease, obesity);
- childhood.
There is no sufficient data on the use of Sustanon-250 during breastfeeding.
Instructions for use of Sustanon-250: method and dosage
Sustanon-250 is injected intramuscularly deeply.
As a rule, the regimen of drug use is determined individually and depends on the patient's response to therapy.
On average, 1 ml is prescribed every 3 weeks.
Side effects
Possible violations when using high doses of Sustanon-250, long-term therapy and / or frequent administration:
- central nervous system: increased nervous excitability, depression, mood changes, change (decrease or increase) in libido;
- genitourinary system: decreased ejaculate volume, gynecomastia, priapism, oligospermia, hypertrophy (functional disorders of the prostate gland);
- digestive system: nausea;
- cardiovascular system: increased blood pressure;
- hematopoietic system: polycythemia;
- musculoskeletal system: myalgia;
- neoplasms (malignant, benign, indeterminate, including polyps and cysts): prostate cancer (the course of diagnosed prostate cancer may also worsen);
- metabolism: edema (fluid retention);
- skin: acne, itching;
- laboratory parameters: functional disorders of the liver, a decrease in the serum concentration of indicators of low and high density lipoproteins and triglycerides, an increase in the level of prostate specific antigen, hypercalcemia;
- local reactions: itching, pain, hyperemia at the injection site.
After discontinuation of therapy, adverse reactions may persist for some time.
Overdose
When administered intramuscularly, Sustanon-250 is not highly toxic. Chronic overdose symptoms include priapism. In this case, it is necessary to interrupt the course of treatment and, after the disappearance of this symptom, resume therapy by reducing the dose.
special instructions
Medical monitoring of the patient's condition should be carried out before the start of therapy, then during the year 1 time in 3 months, then - 1 time per year.
Research Needed:
- digital rectal examination and determination of specific antigen of the prostate gland (in order to exclude benign adenoma and subclinical forms of prostate cancer);
- measurement of hemoglobin and hematocrit (in order to exclude polycythemia).
In patients with anamnestic data on pathologies of the heart, liver or kidneys, the use of Sustanon-250 can lead to the development of complications characterized by edema with / without acute heart failure.
If adverse reactions appear, therapy should be interrupted for a while, after their disappearance, treatment is resumed at a lower dose.
The use of Sustanon-250 off-label, but in order to increase endurance in athletes is a serious health risk. In elderly patients, the drug increases the likelihood of cancer or prostate adenoma.
Influence on the ability to drive vehicles and complex mechanisms
At the moment, there are no reports of the effect of Sustanon-250 on the ability to drive a car and perform potentially dangerous types of work.
Application during pregnancy and lactation
Prescribing the drug during pregnancy is contraindicated due to the likely masculinization of the fetus. There are no reliable clinical data on the use of Sustanon-250 during lactation, therefore, it is not possible to assess the potential harm of the drug to the newborn or its effect on breast milk production.
Pediatric use
Sustanon-250 is not used to treat children under 3 years of age. Children over 3 years old, as well as boys in the prepubertal period, in order to avoid premature puberty and premature closure of the epiphyses, the drug is prescribed with caution.
Drug interactions
The combined use of Sustanon-250 with certain drugs / substances can lead to the development of the following effects:
- insulin or other hypoglycemic drugs used in diabetes mellitus: a decrease in the need for their use (due to an increase in glucose tolerance);
- drugs that inhibit or induce enzymes: an increase or decrease (respectively) in the concentration of testosterone (with combined use, it may be necessary to adjust the dose or breaks between injections);
- coumarin-type anticoagulants: increasing their action (it may be necessary to reduce their dose).
Analogs
The analogues of Sustanon-250 are: Testosterone Enanthate, Testosterone propionate, Omnadren-250, Sustaver from Vermoje, Nebido, Androgel, Methyltestosterone, Andriol.
Terms and conditions of storage
Store at a temperature of 8-30 ° C, protected from light. Keep out of the reach of children.
The shelf life is 5 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Sustanon-250
Mostly reviews about Sustanon-250 are left by athletes who note a quick and successful set of muscle mass when using this drug. There are also positive opinions of patients who have managed to improve their health through testosterone replacement therapy.
Price for Sustanon-250 in pharmacies
On average, the price of 1 ampoule of Sustanon-250 in pharmacy chains is 770–870 rubles.
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
